ABNX — Abionyx Pharma SA Share Price
0.000.00%
Last trade - 00:00- €30.27m
- €32.64m
- €5.25m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.32 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.88% | ||
| Return on Equity | -58.11% | ||
| Operating Margin | -81.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.17 | n/a | n/a | 0.68 | 5.25 | 4.6 | 4.6 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abionyx Pharma SA, formerly known as Cerenis Therapeutics Holding SA, is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Directors
- Emmanuel Huynh CHM (51)
- Cyrille Tupin CEO (45)
- Emmanuel De Fougeroux CFO
- Constance Keyserling COO
- Ronald Barbaras OTH
- Renee Benghozi OTH
- Jean-Louis Dasseux DRC (63)
- Olivier Martinez DRC (50)
- Christian Chavy IND (73)
- Karen Christmas IND (48)
- Laura Coruzzi IND (68)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- March 24th, 2005
- Public Since
- March 30th, 2015
- No. of Employees
- 63
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 28,185,454
- Address
- Bat. D 33-43 Avenue Georges Pompidou, BALMA, 31130
- Web
- https://www.abionyx.com/en/
- Phone
- +33 562249706
- Contact
- Louis-Victor Delouvrier
- Auditors
- Deloitte & Associes
Upcoming Events for ABNX
Half Year 2024 Abionyx Pharma SA Earnings Release
Similar to ABNX
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
What is the Abionyx Pharma SA share price?
As of Today at 19:00 UTC, shares in Abionyx Pharma SA are trading at €1.07. This share price information is delayed by 15 minutes.
How has the Abionyx Pharma SA share price performed this year?
Shares in Abionyx Pharma SA last closed at €1.07 and the price had moved by -43.83% over the past 365 days. In terms of relative price strength the Abionyx Pharma SA share price has underperformed the FTSE Global All Cap Index by -47.27% over the past year.
What are the analyst and broker recommendations for Abionyx Pharma SA?
The overall consensus recommendation for Abionyx Pharma SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Abionyx Pharma SA dividend yield?
Abionyx Pharma SA does not currently pay a dividend.
Does Abionyx Pharma SA pay a dividend?
Abionyx Pharma SA does not currently pay a dividend.
When does Abionyx Pharma SA next pay dividends?
Abionyx Pharma SA does not currently pay a dividend.
How do I buy Abionyx Pharma SA shares?
To buy shares in Abionyx Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Abionyx Pharma SA?
As of the previous close price of €1.07, shares in Abionyx Pharma SA had a market capitalisation of €30.27m.
Where are Abionyx Pharma SA shares listed?
Here are the trading details for Abionyx Pharma SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ABNX
What kind of share is Abionyx Pharma SA?
Based on an overall assessment of its quality, value and momentum Abionyx Pharma SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Abionyx Pharma SA share price forecast for 2024?
The analyst consensus target price for shares in Abionyx Pharma SA is €10.50. That is 877.65% above the last closing price of €1.07.
Analysts covering Abionyx Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.18 for the next financial year.
What is the trend in the Abionyx Pharma SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abionyx Pharma SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -28.47%.
As of the last closing price of €1.07, shares in Abionyx Pharma SA were trading -9.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Abionyx Pharma SA PE Ratio?
The Abionyx Pharma SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €1.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Abionyx Pharma SA?
Abionyx Pharma SA's management team is headed by:
- Emmanuel Huynh - CHM
- Cyrille Tupin - CEO
- Emmanuel De Fougeroux - CFO
- Constance Keyserling - COO
- Ronald Barbaras - OTH
- Renee Benghozi - OTH
- Jean-Louis Dasseux - DRC
- Olivier Martinez - DRC
- Christian Chavy - IND
- Karen Christmas - IND
- Laura Coruzzi - IND